SAR evolution and discovery of benzenesulfonyl matrinanes as a novel class of potential coxsakievirus inhibitors.

MATERIALS & METHODS Fifty-one novel 12N-substituted matrinic acid derivatives were synthesized and evaluated for their anti-coxsackievirus B3 activities. RESULTS Structure-activity relationship studies revealed that the 11-side chain could be determinant for the selectivity index by adjusting overall lipophilicity, and 11-butane was the best one for both potency and druggability. The optimized 35d showed the broad-spectrum anti-coxsackieviruse effects, an excellent pharmacokinetics and a good safety profile. More importantly, it displayed a potential effect for the pleconaril-resistant coxsackievirus B3 as well. Its mode of action is targeting on the viral transcription and translation stage, a different mechanism from that of pleconaril. CONCLUSION Thus, we considered that 35d is a promising anti-enteroviral candidate for the treatment of various diseases infected with coxsackieviruses.

[1]  Dajun Zhang,et al.  Formononetin inhibits enterovirus 71 replication by regulating COX- 2/PGE2 expression , 2015, Virology Journal.

[2]  Jian-Dong Jiang,et al.  Novel N-benzenesulfonyl sophocarpinol derivatives as coxsackie B virus inhibitors. , 2015, ACS medicinal chemistry letters.

[3]  X. Che,et al.  Nephrotic syndrome in hand, foot and mouth disease caused by coxsackievirus A16: a case report. , 2014, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[4]  R. Shao,et al.  Synthesis and biological evaluation of sophoridinol derivatives as a novel family of potential anticancer agents. , 2014, ACS medicinal chemistry letters.

[5]  W. Palmer,et al.  Hand, foot, and mouth disease: Identifying and managing an acute viral syndrome , 2014, Cleveland Clinic Journal of Medicine.

[6]  R. Shao,et al.  Novel N-substituted sophoridinol derivatives as anticancer agents. , 2014, European journal of medicinal chemistry.

[7]  Jian-Dong Jiang,et al.  Synthesis and Biological Evaluation of N‐Substituted Sophocarpinic Acid Derivatives as Coxsackievirus B3 Inhibitors , 2013, ChemMedChem.

[8]  Jian-Dong Jiang,et al.  The antiviral effect of 7-hydroxyisoflavone against Enterovirus 71 in vitro , 2013, Journal of Asian natural products research.

[9]  Jian-Dong Jiang,et al.  N-Substituted Benzyl Matrinic Acid Derivatives Inhibit Hepatitis C Virus (HCV) Replication through Down-Regulating Host Heat-Stress Cognate 70 (Hsc70) Expression , 2013, PloS one.

[10]  E. De Clercq Highlights in antiviral drug research: antivirals at the horizon. , 2013, Medicinal research reviews.

[11]  A. Ko,et al.  Antiviral Effects of Small Interfering RNA Simultaneously Inducing RNA Interference and Type 1 Interferon in Coxsackievirus Myocarditis , 2012, Antimicrobial Agents and Chemotherapy.

[12]  F. Widdel,et al.  Stereochemical investigations reveal the mechanism of the bacterial activation of n-alkanes without oxygen. , 2012, Angewandte Chemie.

[13]  Jian-Dong Jiang,et al.  Design and synthesis of oxymatrine analogues overcoming drug resistance in hepatitis B virus through targeting host heat stress cognate 70. , 2011, Journal of medicinal chemistry.

[14]  A. Reynolds,et al.  Design, synthesis, and structure-affinity relationships of regioisomeric N-benzyl alkyl ether piperazine derivatives as sigma-1 receptor ligands. , 2010, Journal of medicinal chemistry.

[15]  J. Neyts,et al.  9-Arylpurines as a novel class of enterovirus inhibitors. , 2010, Journal of medicinal chemistry.

[16]  W. Kiosses,et al.  Viral Persistence and Chronic Immunopathology in the Adult Central Nervous System following Coxsackievirus Infection during the Neonatal Period , 2009, Journal of Virology.

[17]  E. De Clercq,et al.  Selective inhibitors of picornavirus replication , 2008, Medicinal research reviews.

[18]  B. McManus,et al.  The impact of CVB3 infection on host cell biology. , 2008, Current topics in microbiology and immunology.

[19]  D. Barnard,et al.  Current status of anti-picornavirus therapies. , 2006, Current pharmaceutical design.

[20]  A. Ramsingh,et al.  Coxsackievirus-induced pancreatitis. , 2004, Viral immunology.

[21]  H. Rotbart,et al.  Treatment of picornavirus infections. , 2002, Antiviral research.

[22]  N. Chapman,et al.  The group B coxsackieviruses and myocarditis , 2001, Reviews in medical virology.

[23]  L. Kinnunen,et al.  Molecular epidemiology and evolution of coxsackievirus A9. , 2000, The Journal of general virology.

[24]  T. Hyypiä,et al.  Molecular comparison of coxsackie A virus serotypes. , 1995, Virology.

[25]  S. Tracy A comparison of genomic homologies among the coxsackievirus B group: use of fragments of the cloned coxsackievirus B3 genome as probes. , 1984, The Journal of general virology.